Neuroendocrine Tumors of Old Patients in the West of France

• Conditions: Neuroendocrine Tumors

• Registration Number: NCT03749681
• Lead Sponsor: University Hospital, Brest

Brief Summary

Neuroendocrine cancer remains a poorly known entity. Comprehensive treatment is multidisciplinary involving surgery, radiological and nuclear medicine, and medical. A national network for the management of sporadic and hereditary malignant neuro-ENdocrine Tumor (RENATEN) is in charged of coordinating this specific care. This is part of the French National Cancer INstitute (INCa) Rare Cancer Plan.

The project is in the form of an analysis of elderly population (75 years or over) with a diagnosis of neuroendocrine cancer in the western part of the France (Brittany, Pays de Loire, Normandy, Center and a part of New Aquitaine areas) representing a population of more than 12 millions of inhabitants. Oncogeriatric evaluations, specialized meetings, ...would be analysed in order to improve the care of rare cancer patients.

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-03
• Study First Submitted: 2018-04-05
• Study First Submitted QC: 2018-11-20
• Last Update Submitted: 2018-11-20
• Study First Posted: 2018-11-21
• Last Update Posted: 2018-11-21
• Study Start: 2018-12
• Primary Completion: 2020-03-28
• Study Completion: 2020-03-28

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 306

Inclusion Criteria

• 75 years old or over at the time of diagnosis
• Patient with G1/G2/G3 neuroendocrine tumor diagnosed by pathological analysis
• Patient whose medical file was examined by RENATEN (National Network for the treatment of neuro-ENdocrine sporadic and hereditary disease Tumor) meetings or other multidisciplinary consultation meeting between 01/01/2014 and 31/12/2017
• Patient with care in private and public centers in the West of France

Exclusion Criteria

• Patient with cancer other than a neuroendocrine tumor
• Patient with a G4 neuroendocrine tumor
• Patient who has objected to the study and collection of his medical data
• Refusal of participation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall survival	03/31/2020	statistical analysis (months) with Kaplan meier analysis; data provided by the medical file
Histology, differentiation status	03/31/2020	qualitative description (text)
All anticancer treatment description in neuroendocrine tumors of 3 specific histological grade (G1, 2 or 3)	03/31/2020	statistical analysis (%)
mitotic index and proliferation idex of the tumor	03/31/2020	statistical analysis (%)
Response rate	03/31/2020	statistical analysis (%)
progression free survival	03/31/2020	statistical analysis (months) with Kaplan meier analysis; data provided by the medical file
Tumor description : localization of the tumor (digestive or others) provided by scan or anatomopathologic report	03/31/2020	statistical analysis (%)

Trial Locations

Locations (1)

CHRU de Brest; 🇫🇷 Brest, France